XBI
State Street SPDR S&P Biotech ETF
$145.04−0.24 (−0.17%)Close Nov 18, 2026
Adjusted price
+26.47% total return, past year
Key statistics
- Expense ratio
- 0.35%
- Dividend yield
- 0.38%
- 52-week range
- $113.83$169.55
- All-time high close
- $173.99 on Feb 8, 2021
- From all-time high
- −16.64%
- Max drawdown
- −63.89%
- Volatility
- 30.60%
- Sharpe ratio
- 0.51
- Beta (5Y monthly)
- 0.86
Returns
Total
- 1M
- +0.50%
- YTD
- +19.07%
- 1Y
- +26.47%
Per year
- 3Y
- +26.18%
- 5Y
- +3.61%
- 10Y
- +8.35%
- 20Y
- +11.50%
- Since 2006
- +11.35%
Fund facts
As of Jun 30, 2026- Net assets
- $10.7B
- Holdings
- 161
- Top 10 holdings
- 18.0%
- Stocks
- 99.9%
- Cash
- 5.9%
Sectors
- Health Care
- 99.2%
- Financials
- 0.5%
- Other
- 0.2%
Top holdings
| Holding | Weight (%) |
|---|---|
| State Street Global Advisors | 5.9 |
| APGEApogee Therapeutics, Inc. | 1.5 |
| MRNAModerna, Inc. | 1.4 |
| TWSTTwist Bioscience Corporation | 1.4 |
| ORKAOruka Therapeutics, Inc. | 1.4 |
| KYMRKymera Therapeutics, Inc. | 1.4 |
| VKTXViking Therapeutics, Inc. | 1.3 |
| PRAXPraxis Precision Medicines, Inc. | 1.3 |
| ERASErasca, Inc. | 1.3 |
| RVMDRevolution Medicines, Inc. | 1.2 |